Literature DB >> 27216997

Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.

Sul A Lee1, Mi Jung Lee2, Geun Woo Ryu1, Jong Hyun Jhee1, Hyung Woo Kim1, Seohyun Park1, Su-Young Jung1, Hyung Jung Oh1, Jung Tak Park1, Seung Hyeok Han1, Shin-Wook Kang1, Tae-Hyun Yoo3,4.   

Abstract

UNLABELLED: Abnormal bone dynamics is a major risk factor for cardiovascular disease in patients with chronic kidney disease. The level of serum intact parathyroid hormone (iPTH) is widely used as a bone dynamic marker. We investigated the effect of the mean level of serum iPTH on overall mortality and cardiovascular outcomes in incident dialysis patients.
PURPOSE: Chronic kidney disease-mineral bone disorder (CKD-MBD) is a major risk factor for cardiovascular disease (CVD) in patients with end-stage renal disease (ESRD). CKD-MBD is classified as low- or high-turnover bone disease according to the bone dynamics; both are related to vascular calcification in ESRD. To evaluate the prognostic value of abnormal serum parathyroid hormone (PTH) levels on ESRD patients, we investigated the effects of time-averaged serum intact PTH (TA-iPTH) levels on overall mortality and major adverse cardiac and cerebrovascular events (MACCEs) in incident dialysis patients.
METHODS: Four hundred thirteen patients who started dialysis between January 2009 and September 2013 at Yonsei University Health System were enrolled. The patients were divided into three groups according to TA-iPTH levels during the 12 months after the initiation of dialysis: group 1, <65 pg/ml; group 2, 65-300 pg/ml; and group 3, >300 pg/ml. Cox regression analyses were performed to determine the prognostic value of TA-iPTH for overall mortality and MACCEs.
RESULTS: The mean age of the patients was 57 ± 15 years, and 222 patients (54 %) were men. During the median follow-up of 40.8 ± 29.3 months, 49 patients (12 %) died, and MACCEs occurred in 55 patients (13 %). The multivariate Cox regression analyses demonstrated that a low TA-iPTH level was an independent risk factor for both overall mortality (group 2 as reference; group 1: hazard ratio (HR) = 2.06, 95 % confidence interval (CI) = 1.11-3.83, P = 0.023) and MACCEs (HR = 1.82, 95 % CI = 1.04-3.20, P = 0.036) in incident dialysis patients after adjustment for confounding factors.
CONCLUSION: Low serum TA-iPTH is a useful clinical marker of both overall mortality and MACCEs in patients undergoing incident dialysis, mediated by vascular calcification.

Entities:  

Keywords:  Chronic kidney disease–mineral bone disorder; End-stage renal disease patients; Major adverse cardiac and cerebrovascular events; Time-averaged serum intact PTH; Vascular calcification

Mesh:

Substances:

Year:  2016        PMID: 27216997     DOI: 10.1007/s00198-016-3636-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  35 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.

Authors:  Masafumi Fukagawa; Keitaro Yokoyama; Fumihiko Koiwa; Masatomo Taniguchi; Tetsuo Shoji; Junichiro James Kazama; Hirotaka Komaba; Ryoichi Ando; Takatoshi Kakuta; Hideki Fujii; Msasaaki Nakayama; Yugo Shibagaki; Seiji Fukumoto; Naohiko Fujii; Motoshi Hattori; Akira Ashida; Kunitoshi Iseki; Takashi Shigematsu; Yusuke Tsukamoto; Yoshiharu Tsubakihara; Tadashi Tomo; Hideki Hirakata; Tadao Akizawa
Journal:  Ther Apher Dial       Date:  2013-06       Impact factor: 1.762

Review 3.  Arterial calcification in chronic kidney disease: key roles for calcium and phosphate.

Authors:  Catherine M Shanahan; Matthew H Crouthamel; Alexander Kapustin; Cecilia M Giachelli
Journal:  Circ Res       Date:  2011-09-02       Impact factor: 17.367

4.  Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study.

Authors:  Mathias Haarhaus; Marie-Claude Monier-Faugere; Per Magnusson; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2015-04-02       Impact factor: 8.860

Review 5.  Vitamin D and vascular calcification.

Authors:  Armin Zittermann; Stefanie S Schleithoff; Reiner Koerfer
Journal:  Curr Opin Lipidol       Date:  2007-02       Impact factor: 4.776

6.  Transiliac bone biopsy. Complications and diagnostic value.

Authors:  S D Rao; V Matkovic; H Duncan
Journal:  Henry Ford Hosp Med J       Date:  1980

Review 7.  Vascular calcifications: pathogenesis, management, and impact on clinical outcomes.

Authors:  Jorge B Cannata-Andía; Minerva Rodríguez-García; Natalia Carrillo-López; Manuel Naves-Díaz; Bernardino Díaz-López
Journal:  J Am Soc Nephrol       Date:  2006-12       Impact factor: 10.121

8.  Aortic arch calcification predicts cardiovascular and all-cause mortality in maintenance hemodialysis patients.

Authors:  Mizuki Komatsu; Masayuki Okazaki; Ken Tsuchiya; Hiroshi Kawaguchi; Kosaku Nitta
Journal:  Kidney Blood Press Res       Date:  2014-12-19       Impact factor: 2.687

Review 9.  Adynamic bone disease: from bone to vessels in chronic kidney disease.

Authors:  Jordi Bover; Pablo Ureña; Vincent Brandenburg; David Goldsmith; César Ruiz; Iara DaSilva; Ricardo J Bosch
Journal:  Semin Nephrol       Date:  2014-11       Impact factor: 5.299

10.  Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease.

Authors:  Mhairi K Sigrist; Maarten W Taal; Peter Bungay; Christopher W McIntyre
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-10       Impact factor: 8.237

View more
  14 in total

1.  Parathyroid hormone promotes osteoblastic differentiation of endothelial cells via the extracellular signal-regulated protein kinase 1/2 and nuclear factor-κB signaling pathways.

Authors:  Zhi-Yuan Cheng; Ting Ye; Qiu-Yang Ling; Ting Wu; Gang-Yong Wu; Gang-Jun Zong
Journal:  Exp Ther Med       Date:  2017-11-23       Impact factor: 2.447

Review 2.  Potential application of klotho in human chronic kidney disease.

Authors:  Javier A Neyra; Ming Chang Hu
Journal:  Bone       Date:  2017-01-20       Impact factor: 4.398

3.  Hemodialysis patients with low serum parathyroid hormone levels have a poorer prognosis than those with secondary hyperparathyroidism.

Authors:  Yue Yu; Zongli Diao; Ying Wang; Peiyi Zhou; Rui Ding; Wenhu Liu
Journal:  Ther Adv Endocrinol Metab       Date:  2020-09-21       Impact factor: 3.565

4.  A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial).

Authors:  Yuya Itano; Sawako Kato; Masato Tsuboi; Hirotake Kasuga; Yoshinari Tsuruta; Fumihiko Sato; Manabu Hishida; Takuji Ishimoto; Tomoki Kosugi; Masahiko Ando; Yachiyo Kuwatsuka; Shoichi Maruyama
Journal:  Kidney Int Rep       Date:  2020-09-18

5.  Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study.

Authors:  Denis Fouque; Hubert Roth; Bernadette Darné; Louis Jean-Bouchet; Eric Daugas; Tilman B Drüeke; Thierry Hannedouche; Guillaume Jean; Gérard M London
Journal:  Clin Kidney J       Date:  2017-09-23

6.  Safety of Low-calcium Dialysate and its Effects on Coronary Artery Calcification in Patients Undergoing Maintenance Hemodialysis.

Authors:  Yang Wen; Hua Gan; Zhengrong Li; Ximin Sun; Ying Xiong; Yunfeng Xia
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

7.  Effects of parathyroid hormone and vitamin D supplementation on stroke among patients receiving peritoneal dialysis.

Authors:  Xiaohan You; Ying Zhou; Jianna Zhang; Qiongxiu Zhou; Yanling Shi; Zhen Su; Chaoshen Chen; Rongrong Shao; Ji Zhang
Journal:  BMC Nephrol       Date:  2020-05-18       Impact factor: 2.388

8.  Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients?

Authors:  Elin Isaksson; Martin Almquist; Astrid Seeberger; Gunnar Sterner
Journal:  Clin Exp Nephrol       Date:  2018-02-24       Impact factor: 2.801

9.  The relationship between hemodialysis mortality and the Chinese medical insurance type.

Authors:  Xi Yao; Shaohua Chen; Wenhua Lei; Nan Shi; Weiqiang Lin; Xiaoying Du; Ping Zhang; Jianghua Chen
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

10.  Effects of parathyroidectomy on plasma PTH fragments and heart rate variability in stage 5 chronic kidney disease patients.

Authors:  Huimin Chen; Wenkai Ren; Zhanhui Gao; Ming Zeng; Shaowen Tang; Fangyan Xu; Yaoyu Huang; Lina Zhang; Ying Cui; Guang Yang; Hanyang Qian; Wenbin Zhou; Chun Ouyang; Xueyan Gao; Jing Zhang; Yujie Xiao; Baiqiao Zhao; Jing Wang; Anning Bian; Fan Li; Huiting Wan; Wei Gao; Xiaoyun Wang; Changying Xing; Xiaoming Zha; Ningning Wang
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.